Activated protein C resistance and factor V Leiden in Mexico

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 4, 2008, Pages 428-437

  Majluf Cruz, Abraham ^a,d   Moreno Hernández, Manuel ^a   Ruiz De Chávez Ochoa, Adriana ^a   Monroy García, Rosario ^a   Majluf Cruz, Karim ^a   Guardado Mendoza, Rodolfo ^a   Molina Ávila, Irma ^a   Isordia Salas, Irma ^a   Corona De La Peña, Norma ^a   Vargas Vorackova, Florencia ^b   Vela Ojeda, Jorge ^c   García Chávez, Jaime ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d NONE   (Mexico)

Author keywords

Activated protein C resistance; Factor V Leiden; Native Americans; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; OBSERVATIONAL STUDY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; THROMBOPHILIA; THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDIES; FACTOR V; FEMALE; HUMANS; MALE; MEXICO; MIDDLE AGED; PREVALENCE;

EID: 51849166154     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607306807     Document Type: Article

References (55)

1. Goldhaber SZ Epidemiology of pulmonary embolism and deep vein thrombosis. In: Bloom AL, Forber CD, Thomas DP, Tuddenham ED, eds. Haemostasis and Thrombosis. New York, NY: Churchill Livingstone; 1994: 66-79.
2. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood. 1995 ; 85: 607-614.
3. Malm J., Laurell M., Nilsson IM, Dahlbäck B. Thromboembolic disease: critical evaluation of laboratory investigation. Thromb Haemost. 1992 ; 68: 7-13.
4. Miletich JP, Prescott SM, White R., Majerus PW, Bovill EG Inherited predisposition to thrombosis. Cell. 1993 ; 72: 477-480.
5. Tabernero MD, Tomas JF, Alberca I., Orfao A., López Borrasca A., Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol. 1991 ; 36: 249-254.
6. Dahlbäck B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost. 1995 ; 74: 139-148.
7. Faioni EM, Franchi F., Asti D., Sacchi E., Bernardi F., Mannucci PM Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost. 1993 ; 70: 1067-1071.
8. Voorberg J., Roelse J., Koopman R., et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994 ; 343: 1535-1536.
9. Koster T., Rosendaal FR, de Ronde H., Briet E., Vandenbroucke JP, Bertina RM Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993 ; 342: 1503-1506.
10. Griffin JH, Evatt B., Wideman C., Fernandez JA Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood. 1993 ; 82: 1989-1993.
11. Halbmayer WM, Haushofer A., Schon R., Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis. 1994 ; 5: 51-57.
12. Dahlbäck B. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. J Intern Med. 1995 ; 237: 221-227.
13. Clark P., Walker ID The phenomenon known as acquired activated protein C resistance. Br J Haematol. 2001 ; 115: 767-773.
14. Lisker R., Ramírez E., Babinsky V. Genetic structure of autochthonous populations of Meso-America: Mexico. Hum Biol. 1996, 68: 395-404.
15. Elice F., Fink L., Tricot G., Barlogie B., Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006 ; 134: 399-405.
16. Bertina RM, Koeleman BP, Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 ; 369: 64-67.
17. Instituto Nacional de Estadística, Geografía e Informática. XII Censo Nacional de Población y Vivienda. 2000. Available at: www.inegi.gob.mx. Accessed July 19, 2007.
18. Dahlbäck B., Carlsson M., Svensson PJ Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993 ; 90: 1004-1008.
19. Kisiel W., Canfield WM, Ericsson LH, Davie EW Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry. 1977 ; 16: 5824-5831.
20. Zivelin A., Griffin JH, Xu X., et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997 ; 89: 397-402.
21. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol. 1992 ; 29: 170-176.
22. Kane WH, Davie EW Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood. 1988 ; 71: 539-555.
23. Rees DC, Cox M., Clegg JB World distribution of factor V Leiden. Lancet 1995 ; 346: 1133-1134.
24. Hallam PJ, Millar DS, Krawczak M., Kakkar VV, Cooper DN Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency. J Med Genet 1995 ; 32: 543-545.
25. Cox MJ, Rees DC, Martinson JJ, Clegg JB Evidence for a single origin of factor V Leiden. Br J Haematol. 1996 ; 92: 1022-1025.
26. Castoldi E., Lunghi B., Mingozzi F., Ioannou P., Marcheti G., Bernardi F. New coagulation factor V gene polymorphisms define a single and infrequent haplotype underlying the factor V Leiden mutation in Mediterranean populations and Indians. Thromb Haemost. 1997 ; 78: 1037-1041.
27. Pepe G., Rickards O., Camacho Vanegas O., et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost. 1997 ; 77: 329-331.
28. Hepner M., Roldan A., Pieroni G., et al. Frequency of factor V Arg506 to Gln mutation (FV Leiden) and activated protein C resistance in blood donors in Argentina. A preliminary study. Thromb Haemost. 1997 ; 78 (suppl): 226.
29. Martinez E., Tirado I., Vallve C., et al. Prevalence of resistance to activated protein C in patients with thrombosis in Spanish population. Thromb Haemost. 1997 ; 78 (suppl): 223.
30. Garcia-Gala JM, Alvarez V., Pinto CR, et al. Factor V Leiden (R506Q) and risk of venous thromboembolism: a case-control study based on the Spanish population. Clin Genet 1997 ; 52: 206-210.
31. van der Bom JG, Bots ML, Haverkate F., et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med. 1996 ; 125: 265-269.
32. Kiechl S., Muigg A., Santer P., et al. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation. 1999 ; 99: 614-619.
33. Sakata T., Kario K., Katayama Y., Matsuyama T., Kato H., Miyata T. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Thromb Res. 1996 ; 82: 235-244.
34. De Visser MC, Rosendaal FR, Bertina RM A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 1999 ; 93: 1271-1276.
35. Rodeghiero F., Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999 ; 130: 643-650.
36. Tosetto A., Castaman G., Cappellari A., Rodeghiero F. The VITA Project: inheritability of resistance to activated protein C. Thromb Haemost. 2000 ; 84: 811-814.
37. Gennari L., Blanco A. Alberto MF, Grosso S., Lazzari MA The concomitant presence of lupus anticoagulant, anticardiolipin and anti-[beta]2-glycoprotein I antibodies could be associated with acquired activated protein C resistance in non-systemic lupus erythematosus patients. Br J Haematol. 2003 ; 121: 527-529.
38. Male C., Mitchell L., Julian J., et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood. 2001 ; 97: 844-849.
39. Nojima J., Kuratsune H., Suehisa E., et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol. 2002 ; 118: 577-583.
40. Benedetto C., Marozio L., Tavella AM, Maulà V., Carmignani D., Curti A. Response to activated protein C decreases throughout pregnancy. Acta Obstet Gynecol Scand. 2002 ; 81: 1028-1032.
41. Samama MM, Rached RA, Horellou MH, et al. Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone. Br J Haematol. 2003 ; 123: 327-334.
42. Robertson L., Wu O., Langhorne P., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2005 ; 132: 171-196.
43. Majluf-Cruz A., Silva-Estrada M., Sanchez-Barboza R., et al. Venous thrombosis among patients with AIDS. Clin Appl Thromb Hemost. 2004 ; 10: 19-25.
44. Makris TK, Krespi PG, Hatzizacharias AN, et al. Resistance to activated protein C and FV Leiden mutation in patients with a history of acute myocardial infarction or primary hypertension. Am J Hypertens. 2000 ; 13: 61-65.
45. Olivieri O., Friso S., Manzato F., et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol. 1995 ; 91: 465-470.
46. van Vliet HA, Frolich M., Christella M., et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod. 2004 ; 20: 563-568.
47. Gardiner C., Mackie IJ, Furs SA, Piegsa K., Guillebaud J., Machin SJ Acquired resistance to activated protein C is more pronounced in women receiving combined oral contraceptives containing desogestrel than levonorgestrel and is associated with low protein S levels. Br J Haematol. 2003 ; 121 (suppl 1). 62.
48. Post MS, Rosing J., Van Der Mooren MJ,, et al. Ageing Women and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU). Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol. 2002 ; 119: 1017-1023.
49. Zangari M., Saghafifar F., Anaissie E., et al. Activated protein C resistance in the absence of FV Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002 ; 13: 187-192.
50. De Lucia D., de Vita F., Orditura M., et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. Tumori. 1997 ; 83: 948-952.
51. Green D., Maliekel K., Sushko E., Akhtar R., Soff GA Activated protein C resistance in cancer patients. Haemostasis. 1997 ; 27: 112-118.
52. Haim N., Lanir N., Hoffman R., Haim A., Tsalik M., Brenner B. Acquired protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med. 2001 ; 110: 91-96.
53. De Stefano V., Leone G. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologica. 1995 ; 80: 344-356.
54. Dahlbäck B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost. 1991 ; 66: 49-61.
55. Guerrero F., Arnaud C., Nguyen F., Boneu B., Sié P. Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation. Thromb Haemost. 2006 ; 95: 728-734.